MODIFIED EXTRACELLULAR DOMAIN OF GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR (G-CSFR) AND CYTOKINES BINDING SAME
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 15. Apr. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
VOLKERS GESA [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-04-15, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
CA3151471 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003605426 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003605426 | ||
| 003 | DE-627 | ||
| 005 | 20240426160935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240419s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003605426 | ||
| 035 | |a (EPA)CA3151471 | ||
| 035 | |a (EPA)75436957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a VOLKERS GESA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MODIFIED EXTRACELLULAR DOMAIN OF GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR (G-CSFR) AND CYTOKINES BINDING SAME |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-04-15, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 | ||
| 520 | |a Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a FULLER MEGAN |e verfasserin |4 aut | |
| 700 | 0 | |a BOULANGER MARTIN J |e verfasserin |4 aut | |
| 700 | 0 | |a DIXIT SURJIT BHIMARAO |e verfasserin |4 aut | |
| 700 | 0 | |a NELSON BRAD |e verfasserin |4 aut | |
| 700 | 0 | |a SANCHES MARIO |e verfasserin |4 aut | |
| 700 | 0 | |a LOVELESS BIANCA |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 15. Apr. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75436957/publication/CA3151471A1?q=CA3151471 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 04 | ||